Skip to main content

Cognition Therapeutics, Inc.

corporate_fare Company Profile

Cognition Therapeutics, Inc.

CGTX·NASDAQ·Life Sciences·CIK 0001455365

The company is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. Many of these diseases currently have limited or no approved therapies. The company aims to develop disease-modifying treatments for patients with these degenerative disorders. Its lead product candidate is zervimesine, also known as CT1812, an orally delivered small molecule. Zervimesine is designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including β-amyloid (Aβ) and ɑ-synuclein, which are linked to diseases like Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024. The company initially focused on developing zervimesine for AD, believing it displaces Aβ oligomers from neuronal receptors, potentially slowing synapse loss and cognitive decline in AD. Direct healthcare costs for AD and other dementias in the United States are estimated to exceed $350 billion, with approximately 7 million people diagnosed with AD in the U.S. and an estimated 35 million globally. Top-line results from the Phase 2 COG0201 (SHINE) study of zervimesine in mild-to-moderate AD were reported in 2024. Enrollment is ongoing in the COG0203 (START) Phase 2 study of zervimesine for patients with Mild Cognitive Impairment (MCI) and early-stage AD. The START clinical trial is conducted in collaboration with the Alzheimer's Clinical Trial Consortium (ACTC) and both studies are supported by grant awards totaling $110 million from the National Institute of Aging (NIA).

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CGTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for CGTX spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Cognition Q3 Loss Narrows to $4.1M; Cash Runs Into Q4 2027 as Nasdaq Deficiency Looms
  • Cognition Therapeutics Receives Nasdaq Minimum-Bid Deficiency Notice, Has Until May 3, 2027 to Cure
  • Cognition Confirms FDA Alignment on Phase 3 Zervimesine Trial in DLB
  • FDA Signs Off on Pivotal Phase 3 Design for Cognition's DLB Drug
  • Cognition Therapeutics Secures Composition of Matter Patent for Zervimesine Through 2045

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$23.49M
Diluted EPS
-$0.32
Op. Cash Flow
-$24.59M
Operating Income
-$47.8M
Cash & Equivalents
$36.81M
Debt / Equity
0.00×
Shares Outstanding
88.9M sh
Source: 10-K · filed 2026-03-26 · accession 0001104659-26-034880

Short Interest & Short Volume

15.27 days to cover

FINRA reported short interest of 6,916,762 shares in CGTX as of the October 30, 2026 settlement, a 1.7% decrease from the prior period — about 15.3 days to cover at its recent average daily volume. On November 20, 2026, 53.0% of CGTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,916,762 shares as of October 30, 2026
Change vs prior period▼ 1.7%
Days to cover15.27 at avg daily volume of 453,080
Daily short volume (FINRA facilities)53.0% of 404,908 shares on November 20, 2026
5-day average short volume43.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.58 -0.38% today
52-week range · as of 2026-11-05 $0.5501 – $1.82
Market cap
$55.37M
Volume
665.4K (1.2× avg)
3-mo avg 550.8K
Live data · 2026-11-22 00:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6833
Real-time Price: $0.580 info
Change: -$0.1033 (-15%) info
Market Cap: $55.368M info
CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.580 info
Change: -$0.1033 (-15%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.580 info
Change: -$0.220 (-28%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.580 info
Change: -$0.2195 (-27%) info
Market Cap: $55.368M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.580 info
Change: -$0.285 (-33%) info
Market Cap: $55.368M info
CGTX
Aug 07, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.580 info
Change: -$0.550 (-49%) info
Market Cap: $55.368M info
CGTX
Aug 06, 2026, 4:26 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $0.580 info
Change: -$0.540 (-48%) info
Market Cap: $55.368M info
CGTX
Jun 24, 2026, 7:43 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $0.580 info
Change: -$1.16 (-67%) info
Market Cap: $55.368M info
CGTX
Jun 24, 2026, 7:39 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $0.580 info
Change: -$1.08 (-65%) info
Market Cap: $55.368M info
CGTX
Jun 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.25
Real-time Price: $0.580 info
Change: -$0.667 (-53%) info
Market Cap: $55.368M info
CGTX
Jun 04, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $0.580 info
Change: -$0.830 (-59%) info
Market Cap: $55.368M info
CGTX
May 21, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.26
Real-time Price: $0.580 info
Change: -$0.680 (-54%) info
Market Cap: $55.368M info
CGTX
May 21, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.580 info
Change: -$0.630 (-52%) info
Market Cap: $55.368M info
CGTX
May 08, 2026, 7:41 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $0.580 info
Change: -$0.6091 (-51%) info
Market Cap: $55.368M info
CGTX
May 07, 2026, 4:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.580 info
Change: -$0.580 (-50%) info
Market Cap: $55.368M info
CGTX
Mar 26, 2026, 7:40 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.580 info
Change: -$0.525 (-48%) info
Market Cap: $55.368M info
CGTX
Mar 26, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $0.580 info
Change: -$0.525 (-48%) info
Market Cap: $55.368M info
CGTX
Mar 26, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $0.580 info
Change: -$0.540 (-48%) info
Market Cap: $55.368M info
CGTX
Mar 17, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.580 info
Change: -$0.500 (-46%) info
Market Cap: $55.368M info
CGTX
Mar 02, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.580 info
Change: -$0.500 (-46%) info
Market Cap: $55.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets